• Turtle Creek Asset Management recently added Medpace Holdings, Inc. to its Q1 2026 portfolio, citing the CRO’s clinician-led focus on small and mid-sized biopharma clients and its strong cash flow generation.
• The move shines a light on Medpace’s founder-led model, deep MD and PhD bench, and disciplined share repurchases, including buying back nearly 10% of its stock last year.
• We’ll now examine how Turtle Creek’s endorsement of Medpace’s clinician-led, high-science model could influence the company’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Medpace Holdings Investment Narrative Recap

To own Medpace, you need to be comfortable with a focused, clinician-led CRO that leans heavily on small and mid-sized biopharma clients and strong cash generation. Turtle Creek’s new position largely reinforces that story rather than changing it, and it does not materially alter the near term focus on backlog conversion as a key catalyst or client concentration and funding pressure on smaller biotech customers as the main risk.

The most relevant recent announcement here is Medpace’s Q1 2026 earnings, which showed revenue of US$706.6 million and net income of US$123.9 million. That financial backdrop helps explain why an investor like Turtle Creek might be comfortable highlighting cash flow and disciplined share repurchases, even as the market weighs near term booking trends and the potential impact of any slowdown or cancellations among its more concentrated client base.

Yet, behind the strong clinician-led pitch, investors should still be aware of the concentration risk if one of Medpace’s largest clients were to...

Medpace Holdings' narrative projects $3.3 billion revenue and $615.9 million earnings by 2029. This requires 9.5% yearly revenue growth and about a $165 million earnings increase from $451.1 million today.

Uncover how Medpace Holdings' forecasts yield a $500.08 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already banking on Medpace reaching about US$3.8 billion of revenue and US$670.8 million of earnings, so Turtle Creek’s endorsement and any shift in client or AI related risks could either reinforce or challenge those upbeat assumptions, depending on how the story unfolds from here.

Explore 7 other fair value estimates on Medpace Holdings - why the stock might be worth as much as 57% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Medpace Holdings research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Medpace Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medpace Holdings' overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Find 45 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.